APOTEA Apotea AB (publ)

9.991USD101.50 SEK · STO+0.20%Mkt Cap: 1.04B USDP/E: 40.76

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, …

Key Statistics

Company
Market Cap1.04B USD
Enterprise Value1.06B USD
Revenue (TTM)768.52M USD
Gross Profit190.72M USD
Net Income (TTM)22.51M USD
Revenue/Share7.38 USD
Last Price9.991 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees713
CountrySE
SectorHealthcare
IndustryPharmaceutical Retailers
ISINSE0023313762
Valuation
P/E (Trailing)40.76
P/E (Forward)27.51
PEG—
EV/EBITDA22.16
EV/Revenue1.37
P/S1.35
P/B10.24
EPS (TTM)0.25 USD
EPS (Forward)—
52W Range
5.35789% of range10.55
52W High10.55 USD
52W Low5.357 USD
Profitability
Gross Margin26.90%
Oper. Margin4.32%
EBITDA Margin6.20%
Profit Margin3.17%
ROE27.10%
ROA11.55%
ROIC20.44%
ROCE27.39%
Growth
Revenue Growth12.50%
Earnings Growth18.10%
Cash Flow & Leverage
Operating CF32.81M USD
CapEx (TTM)21.22M USD
FCF Margin1.05%
FCF Yield0.78%
Net Debt15.03M USD
Net Debt/EBITDA0.32
Net Debt/FCF1.86
Balance Sheet
Debt/Equity0.39
Current Ratio1.59
Quick Ratio0.63
Book Value/Sh0.98 USD
Cash/Share0.10 USD
Dividends
Fwd Div Rate0.06 USD
Trail. Div Rate0.06 USD
Div. Yield0.59%
5Y Avg Yield—
Payout Ratio24.10%
Ex-Div DateMay 27, 2026
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.38 USD
Upside (mean)+3.9%
Target Range9.548 USD – 11.22 USD
9.548+3.9% to mean11.22
# Analysts2
Ownership
Shares Out.104.07M
Float65.98M
Insiders39.71%
Institutions41.28%
Technical
SMA 508.752 (+14.1%)
SMA 2007.345 (+36.0%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)294.07K
Avg Vol (10d)375.11K
Technical Indicators
RSI (14)66.0
MACD3.7670
MACD Signal4.1233
MACD Hist.-0.3563
BB Upper10.69 USD
BB Middle9.658 USD
BB Lower8.627 USD
BB Width21.34%
ATR (14)0.2732 USD
Vol Ratio (20d)1.92x

About Apotea (STO: APOTEA)

›

Apotea (STO: APOTEA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Pharmaceutical Retailers industry, part of the Healthcare sector, and reports about 713 employees.

The shares were at 101.50 SEK on 19 November 2026, up 16.7% over 52 weeks. Its 52-week range is 54.42 SEK to 107.20 SEK: the price is 5.3% below the high and 86.5% above the low.

At a market capitalisation of 10.56B SEK, it trades at 40.8 times trailing earnings and 27.5 times forward earnings. The median trailing P/E of its 4 largest Pharmaceutical Retailers peers is 21.9, a premium of 86% for APOTEA. It pays a dividend yielding 0.59% (it pays out 24% of its earnings), against a median of 3.94% among the dividend payers in that peer group.

Apotea reports return on equity of 27.1%, an operating margin of 4.3% and revenue up 12.5% year over year.

Its debt exceeds its cash by 152.70M SEK, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 105.50 SEK is 3.9% above the current price. The next earnings report is expected on 4 February 2027.